

To whom it may concern:

In March 2023, Werfen, S.A., through one of its subsidiaries, acquired the entire share capital of Immucor, Inc., a group of companies specialized in transfusion and transplantation. As a consequence of the acquisition, Werfen, S.A. is the owner, through its subsidiaries, of the entire group of companies headed by Immucor, Inc. and its subsidiaries.

For information purposes, the Immucor group companies in charge of manufacturing transfusion and transplant products are the following:

- Immucor, Inc. (USA)
- Dominion Biologicals Limited (Canada)
- Immucor GTI Diagnostics Inc. (USA)
- Bioarray Solutions Ltd. (USA)
- Immucor Medizinische Diagnostik GmbH (Germany)

As a consequence of the acquisition by Werfen of the Immucor group, an integration process is being carried out between both groups of companies. Among others, the Immucor group companies are adopting the "Werfen" brand as their own brand.

Notwithstanding the foregoing, although Immucor representatives now use the "Werfen" brand, this is only a mere change of brand. There is no change to the legal entity nor the physical manufacturing facility responsible for design and manufacture of products. Therefore, all the products manufactured in the aforementioned centers, the technical documentation, product labeling, QMS certifications and product certifications remain unchanged.

Please feel free to contact us for any questions you may have.

Sincerely,

A stylized, handwritten signature in blue ink, consisting of several overlapping, sweeping strokes.

Anna Cano
Senior Legal Counsel
Werfen, S.A.

A handwritten signature in blue ink, written in a cursive style, reading "Gary Lawson".

Gary Lawson
VP, Quality Assurance and Regulatory
Affairs, Transfusion and Transplant